The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Strongbridge's deal with Novo Nordisk over Macrilen tops up the former's cash pile and pays off debt just 10 months after the company licensed the project from…